{'fraction_non_alphanumeric': 0.03633217993079585, 'fraction_numerical': 0.006920415224913495, 'mean_word_length': 5.655172413793103, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Serum sickness following streptokinase therapy.

The clinical efficacy of thrombolytic therapy using streptokinase and urokinase is now well established [1 -4], as are the sometimes serious complications that may accompany systemic therapy, including bleeding, fever, and/or allergic reactions. To minimize these complications, we now perform localized intraarterial low-dose infusions of either streptokinase or urokinase directly onto thrombi [5, 6]. A recent case showed that, although local low-dose therapy may avoid many of the bleeding complications, dose-independent re-